{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": -0.3805624, "regularMarketPrice": 146.59, "exchange": "NYQ", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "messageBoardId": "finmb_141885706", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1357137000000, "priceHint": 2, "preMarketChange": 0.11000061, "preMarketChangePercent": 0.07503964, "preMarketTime": 1684231777, "earningsTimestampEnd": 1690806600, "trailingAnnualDividendRate": 5.78, "trailingPE": 34.491764, "trailingAnnualDividendYield": 0.03927965, "epsTrailingTwelveMonths": 4.25, "epsForward": 11.02, "epsCurrentYear": 10.94, "priceEpsCurrentYear": 13.399452, "sharesOutstanding": 1764290048, "bookValue": 7.525, "fiftyDayAverage": 155.4992, "fiftyDayAverageChange": -8.90921, "fiftyDayAverageChangePercent": -0.05729425, "twoHundredDayAverage": 150.651, "twoHundredDayAverageChange": -4.0610046, "twoHundredDayAverageChangePercent": -0.026956374, "marketCap": 258627272704, "forwardPE": 13.302177, "priceToBook": 19.480398, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "tradeable": false, "cryptoTradeable": false, "preMarketPrice": 146.7, "regularMarketChange": -0.55999756, "regularMarketTime": 1684180987, "regularMarketDayHigh": 148.9, "regularMarketDayRange": "145.66 - 148.9", "regularMarketDayLow": 145.66, "regularMarketVolume": 4391156, "regularMarketPreviousClose": 147.15, "bid": 146.2, "ask": 147.51, "bidSize": 8, "askSize": 18, "fullExchangeName": "NYSE", "financialCurrency": "USD", "regularMarketOpen": 147.67, "averageDailyVolume3Month": 5846506, "averageDailyVolume10Day": 4632970, "fiftyTwoWeekLowChange": 12.5, "fiftyTwoWeekLowChangePercent": 0.09322097, "fiftyTwoWeekRange": "134.09 - 168.11", "fiftyTwoWeekHighChange": -21.520004, "fiftyTwoWeekHighChangePercent": -0.12801145, "fiftyTwoWeekLow": 134.09, "fiftyTwoWeekHigh": 168.11, "dividendDate": 1684108800, "earningsTimestamp": 1682600400, "earningsTimestampStart": 1690461000, "displayName": "AbbVie", "symbol": "ABBV"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "fullTimeEmployees": 50000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 68, "title": "Chairman & CEO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": {"raw": 6948244, "fmt": "6.95M", "longFmt": "6,948,244"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 43528872, "fmt": "43.53M", "longFmt": "43,528,872"}}, {"maxAge": 1, "name": "Mr. Robert A. Michael", "age": 52, "title": "Vice Chairman & Pres", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": {"raw": 3998042, "fmt": "4M", "longFmt": "3,998,042"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 13150419, "fmt": "13.15M", "longFmt": "13,150,419"}}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 54, "title": "Exec. VP & CFO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 2972736, "fmt": "2.97M", "longFmt": "2,972,736"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 5172329, "fmt": "5.17M", "longFmt": "5,172,329"}}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 59, "title": "Exec. VP of Operations", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": {"raw": 2576755, "fmt": "2.58M", "longFmt": "2,576,755"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 28534760, "fmt": "28.53M", "longFmt": "28,534,760"}}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 53, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 2983231, "fmt": "2.98M", "longFmt": "2,983,231"}, "exercisedValue": {"raw": 2777988, "fmt": "2.78M", "longFmt": "2,777,988"}, "unexercisedValue": {"raw": 10864175, "fmt": "10.86M", "longFmt": "10,864,175"}}, {"maxAge": 1, "name": "Dr. Thomas J. Hudson M.D.", "age": 60, "title": "Sr. VP of R&D and Chief Scientific Officer", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "VP of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 56, "title": "Exec. VP & Chief HR Officer", "yearBorn": 1966, "fiscalYear": 2013, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Carrie C. Strom", "age": 44, "title": "Sr. VP of AbbVie & Pres of Global Allergan Aesthetics", "yearBorn": 1978, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Rae L. Livingston", "title": "Chief Equity Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}